The historical rank and industry rank for Revance Therapeutics's Pretax Margin % or its related term are showing as below:
RVNC'
s Pretax Margin % Range Over the Past 10 Years
Min: -46025.57 Med: -10085.1 Max: -138.3
Current: -138.3
RVNC's Pretax Margin % is ranked better than 52% of 1027
companies
in the Biotechnology industry
Industry Median: -176.72
vs RVNC: -138.30
Revance Therapeutics Pretax Margin % Historical Data
The historical data trend for Revance Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Revance Therapeutics's Pretax Margin %
For the Biotechnology subindustry, Revance Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revance Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Revance Therapeutics's Pretax Margin % falls into.
Revance Therapeutics Pretax Margin % Calculation
Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.
Revance Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Revance Therapeutics Pretax Margin % Related Terms
Thank you for viewing the detailed overview of Revance Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Revance Therapeutics (Revance Therapeutics) Business Description
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RVNC has been successfully added to your 